Effect of ADRB2 polymorphisms on the efficacy of salmeterol and tiotropium in preventing COPD exacerbations: A prespecified substudy of the POET-COPD trial

The Lancet Respiratory Medicine

Volumn 2, Issue 1, 2014, Pages 44-53

  Rabe, Klaus F ^a   Fabbri, Leonardo M ^b   Israel, Elliot ^c   Kögler, Harald ^d   Riemann, Kathrin ^d   Schmidt, Hendrik ^d   Glaab, Thomas ^d   Vogelmeier, Claus F ^e  

^a UNIVERSITY OF KIEL   (Germany)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^e UNIVERSITY HOSPITAL GIESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR; CORTICOSTEROID; GENOMIC DNA; PLACEBO; SALMETEROL; TIOTROPIUM BROMIDE; BRONCHODILATING AGENT; SALBUTAMOL; SCOPOLAMINE DERIVATIVE;

ADRB2 GENE; ADULT; ARTICLE; BLOOD SAMPLING; CHEST TIGHTNESS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; COUGHING; DISEASE EXACERBATION; DNA EXTRACTION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; DYSPNEA; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; OUTCOME ASSESSMENT; PHARMACOGENETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE NUCLEOTIDE POLYMORPHISM; SPUTUM; UNSPECIFIED SIDE EFFECT; WHEEZING; ACUTE DISEASE; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COMPARATIVE STUDY; FORCED EXPIRATORY VOLUME; GENETIC POLYMORPHISM; GENETICS; PHYSIOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTOR; VITAL CAPACITY;

ACUTE DISEASE; ALBUTEROL; BRONCHODILATOR AGENTS; DOUBLE-BLIND METHOD; FEMALE; FORCED EXPIRATORY VOLUME; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECEPTORS, ADRENERGIC, BETA-2; RISK FACTORS; SCOPOLAMINE DERIVATIVES; VITAL CAPACITY;

EID: 84891372240     PISSN: 22132600     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2213-2600(13)70248-0     Document Type: Article

References (28)

1. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease Global Initiative for Chronic Obstructive Lung Disease, (accessed May 31, 2013). http://www.goldcopd.org/guidelines-global-strategy-for-diagnosis-management.html.
2. Hersh CP Pharmacogenetics of chronic obstructive pulmonary disease: challenges and opportunities. Pharmacogenomics 2010, 11:237-247.
3. Tse SM, Tantisira K, Weiss ST The pharmacogenetics and pharmacogenomics of asthma therapy. Pharmacogenomics J 2011, 11:383-392.
4. 2-adrenergic receptor function, response, and regulation. J Allergy Clin Immunol 2006, 117:18-24.
5. 2-agonist therapy: a pharmacogenetic analysis of two randomised studies. Lancet 2007, 370:2118-2125.
6. 2-Receptor polymorphisms in patients receiving salmeterol with or without fluticasone propionate. Am J Respir Crit Care Med 2010, 181:676-687.
7. Israel E, Chinchilli VM, Ford JG, et al. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet 2004, 364:1505-1512.
8. Taylor DR, Hancox RJ Interactions between corticosteroids and β agonists. Thorax 2000, 55:595-602.
9. Wechsler ME, Lehman E, Lazarus SC, et al. β-Adrenergic receptor polymorphisms and response to salmeterol. Am J Respir Crit Care Med 2006, 173:519-526.
10. 2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trial. Lancet 2009, 374:1754-1764.
11. Bleecker ER, Meyers DA, Bailey WC, et al. ADRB2 polymorphisms and budesonide/formoterol responses in COPD. Chest 2012, 142:320-328.
12. 2 adrenergic receptor and bronchodilator response, bronchial hyperresponsiveness, and rate of decline in lung function in smokers. Thorax 2003, 58:703-707.
13. 2 agonist and glucocorticoid according to ADRB2 polymorphism in patients with chronic obstructive pulmonary disease. Lung 2008, 186:381-386.
14. 2-adrenoreceptor genotypes with bronchodilatory effect of tiotropium in COPD. Respirology 2008, 13:346-352.
15. 2-Adrenergic receptor genetic polymorphisms and short-term bronchodilator responses in patients with COPD. Chest 2007, 132:1485-1492.
16. Kim WJ, Hersh CP, DeMeo DL, Reilly JJ, Silverman EK Genetic association analysis of COPD candidate genes with bronchodilator responsiveness. Respir Med 2009, 103:552-557.
17. 2-Adrenergic receptor haplotype and bronchodilator response to salbutamol in patients with acute exacerbations of COPD. Med Sci Monit 2008, 14:CR392-CR398.
18. Vogelmeier C, Hederer B, Glaab T, et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 2011, 364:1093-1103.
19. Beeh KM, Hederer B, Glaab T, et al. Study design considerations in a large COPD trial comparing effects of tiotropium with salmeterol on exacerbations. Int J Chron Obstruct Pulmon Dis 2009, 4:119-125.
20. Yelensky R, Li Y, Lewitzky S, et al. A pharmacogenetic study of ADRB2 polymorphisms and indacaterol response in COPD patients. Pharmacogenomics J 2012, 12:484-488.
21. Rennard SI, Tashkin DP, McElhattan J, et al. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial. Drugs 2009, 69:549-565.
22. Tashkin DP, Rennard SI, Martin P, et al. Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial. Drugs 2008, 68:1975-2000.
23. Rabe KF, Fabbri LM, Vogelmeier C, et al. Seasonal distribution of COPD exacerbations in the Prevention of Exacerbations with Tiotropium in COPD trial. Chest 2013, 143:711-719.
24. van der Valk P, Monninkhof E, van der Palen J, Zielhuis G, van Herwaarden C Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study. Am J Respir Crit Care Med 2002, 166:1358-1363.
25. 2-Adrenergic receptor polymorphisms, asthma and COPD: two large population-based studies. Eur Respir J 2012, 39:558-566.
26. 2-adrenergic receptor genotypes on signal transduction in human airway smooth muscle cells. Am J Respir Cell Mol Biol 1995, 13:25-33.
27. Decramer ML, Chapman KR, Dahl R, et al. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study. Lancet Respir Med 2013, 1:524-533.
28. 2-adrenergic receptor and asthma. Am J Respir Crit Care Med 1997, 156:S156-S162.